Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The Company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy which has completed Phase 1 clinical trial. It develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.

Edgewise Therapeutics, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

BOULDER, COLO., SEPT. 2, 2026 /PRNEWSWIRE/ -- EDGEWISE THERAPEUTICS, INC. ("EDGEWISE" OR THE "COMPANY"), (NASDAQ: EWTX), A LEADING CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON CARDIOVASCULAR DISEASES, TODAY ANNOUNCED THAT ON AUGUST 31, 2026, EDGEWISE GRANTED INDUCEMENT STOCK OPTIONS TO PURCHASE A TOTAL OF 21,000 SHARES OF EDGEWISE'S COMMON STOCK AND AWARDS OF INDUCEMENT RESTRICTED STOCK UNITS (EACH, AN "RSU AWARD") COVERING A TOTAL OF 10,501 SHARES OF EDGEWISE'S COMMON STOCK TO 4 NEW NON-EXECUTIVE EMPLOYEES IN CONNECTION WITH THE COMMENCEMENT OF THEIR EMPLOYMENT, PURSUANT TO EDGEWISE'S 2024 INDUCEMENT EQUITY INCENTIVE PLAN (THE "INDUCEMENT PLAN").

EDGEWISE THERAPEUTICS REPORTS INDUCEMENT GRANTS AS PERMITTED BY THE NASDAQ LISTING RULES

 PRESENTATION HIGHLIGHTS POSITIVE TOP-LINE DATA FROM 12-WEEK PHASE 2CIRRUS-HCM TRIAL WITH EDG-7500 IN OBSTRUCTIVE AND NONOBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY (HCM)  BOULDER, COLO., AUG. 24, 2026 /PRNEWSWIRE/ -- EDGEWISE THERAPEUTICS, INC. (NASDAQ: EWTX), A LEADING CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON CARDIOVASCULAR DISEASES, TODAY ANNOUNCED THAT THE CIRRUS-HCM ABSTRACT WAS SELECTED FOR A LATE-BREAKING SCIENCE PRESENTATION AT THE EUROPEAN SOCIETY OF CARDIOLOGY (ESC) CONGRESS, TAKING PLACE AUGUST 28-31 IN MUNICH, GERMANY.

EDGEWISE THERAPEUTICS ANNOUNCES UPCOMING LATE-BREAKING SCIENCE PRESENTATION AT THE EUROPEAN SOCIETY OF CARDIOLOGY (ESC) CONGRESS 2026

 ANNOUNCED POSITIVE TOP-LINE DATA FROM 12-WEEK PHASE 2 CIRRUS-HCM TRIAL WITH EDG-7500 IN OBSTRUCTIVE AND NONOBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY (HCM)   COMPLETED SALE OF SEVASEMTEN AND MUSCULAR DYSTROPHY BUSINESS TO SERVIER FOR UP TO $2.65 BILLION IN JULY 2026, STRENGTHENING THE BALANCE SHEET, SHARPENING FOCUS ON THE CARDIOVASCULAR PIPELINE  BOULDER, COLO., AUG. 6, 2026 /PRNEWSWIRE/ -- EDGEWISE THERAPEUTICS, INC. (NASDAQ: EWTX), A LEADING CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON CARDIOVASCULAR DISEASES, TODAY REPORTED FINANCIAL RESULTS FOR THE SECOND QUARTER OF 2026 AND RECENT BUSINESS HIGHLIGHTS.

EDGEWISE THERAPEUTICS REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS

 EDGEWISE RECEIVES $1.55 BILLION IN UPFRONT CASH AND IS ELIGIBLE TO RECEIVE UP TO $1.1 BILLION IN REGULATORY AND COMMERCIAL MILESTONES   TRANSACTION CREATES STRATEGICALLY FOCUSED CARDIOVASCULAR COMPANY   UPFRONT PROCEEDS EXPECTED TO FULLY FUND EDG-7500 DEVELOPMENT THROUGH POTENTIAL APPROVAL  BOULDER, COLO., JULY 13, 2026 /PRNEWSWIRE/ --EDGEWISE THERAPEUTICS, INC. (NASDAQ: EWTX), A LEADING CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON CARDIOVASCULAR DISEASES, TODAY ANNOUNCED THE SUCCESSFUL COMPLETION OF ITS PREVIOUSLY ANNOUNCED DEFINITIVE AGREEMENT UNDER WHICH SERVIER, AN INDEPENDENT INTERNATIONAL PHARMACEUTICAL GROUP GOVERNED BY A FOUNDATION, ACQUIRED SEVASEMTEN AND EDGEWISE'S MUSCULAR DYSTROPHY BUSINESS FOR $1.55 BILLION IN UPFRONT CASH CONSIDERATION AND UP TO $1.1 BILLION IN ADDITIONAL MILESTONE PAYMENTS, FOR AGGREGATE POTENTIAL CONSIDERATION OF UP TO $2.65 BILLION.

EDGEWISE THERAPEUTICS COMPLETES SALE OF SEVASEMTEN FOR UP TO $2.65 BILLION, STRENGTHENING BALANCE SHEET AND CENTERING COMPANY FOCUS ON CARDIOVASCULAR PIPELINE

BOULDER, COLO., JULY 1, 2026 /PRNEWSWIRE/ --EDGEWISE THERAPEUTICS, INC. ("EDGEWISE" OR THE "COMPANY"), (NASDAQ: EWTX), A LEADING MUSCLE DISEASE BIOPHARMACEUTICAL COMPANY DEVELOPING NOVEL THERAPEUTICS FOR MUSCULAR DYSTROPHIES AND SERIOUS CARDIAC CONDITIONS, TODAY ANNOUNCED THAT ON JUNE 30, 2026, EDGEWISE GRANTED INDUCEMENT STOCK OPTIONS TO PURCHASE A TOTAL OF 16,500 SHARES OF EDGEWISE'S COMMON STOCK TO 2 NEW NON-EXECUTIVE EMPLOYEES IN CONNECTION WITH THE COMMENCEMENT OF THEIR EMPLOYMENT, PURSUANT TO EDGEWISE'S 2024 INDUCEMENT EQUITY INCENTIVE PLAN (THE "INDUCEMENT PLAN").

 NO RELATIONSHIP OBSERVED BETWEEN EDG-7500 EXPOSURE AND LVEF; NO LVEF REDUCTIONS BELOW 50%   CONSISTENT AND CLINICALLY MEANINGFUL IMPROVEMENTS OBSERVED IN ECHOCARDIOGRAM PARAMETERS, BIOMARKERS, SYMPTOMS AND FUNCTIONAL STATUS ACROSS OBSTRUCTIVE AND NONOBSTRUCTIVE HCM   EDG-7500 ADMINISTRATION CONTINUED TO BE GENERALLY WELL TOLERATED   COMPANY TO HOST WEBCAST TODAY AT 8:30 A.M. EASTERN TIME  BOULDER,COLO.

EDGEWISE THERAPEUTICS ANNOUNCES POSITIVE TOP-LINE DATA FROM 12-WEEK PHASE 2 CIRRUS-HCM TRIAL WITH EDG-7500 IN OBSTRUCTIVE AND NONOBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY (HCM)

BOULDER, COLO., JUNE 3, 2026 /PRNEWSWIRE/ -- EDGEWISE THERAPEUTICS, INC. ("EDGEWISE" OR THE "COMPANY"), (NASDAQ: EWTX), A LEADING MUSCLE DISEASE BIOPHARMACEUTICAL COMPANY DEVELOPING NOVEL THERAPEUTICS FOR MUSCULAR DYSTROPHIES AND SERIOUS CARDIAC CONDITIONS, TODAY ANNOUNCED THAT ON MAY 29, 2026, EDGEWISE GRANTED INDUCEMENT STOCK OPTIONS TO PURCHASE A TOTAL OF 74,000 SHARES OF EDGEWISE'S COMMON STOCK TO 4 NEW NON-EXECUTIVE EMPLOYEES IN CONNECTION WITH THE COMMENCEMENT OF THEIR EMPLOYMENT, PURSUANT TO EDGEWISE'S 2024 INDUCEMENT EQUITY INCENTIVE PLAN (THE "INDUCEMENT PLAN").

 EDGEWISE TO RECEIVE $1.55 BILLION IN UPFRONT CASH CONSIDERATION AND IS ELIGIBLE TO RECEIVE UP TO $1.1 BILLION IN REGULATORY AND COMMERCIAL MILESTONES   TRANSACTION CREATES FOCUSED CARDIOVASCULAR COMPANY WITH ENHANCED STRATEGIC CLARITY  UPFRONT PROCEEDS EXPECTED TO FULLY FUND EDG-7500 DEVELOPMENT THROUGH POTENTIAL APPROVAL  ON TRACK TO REPORT 12-WEEK CIRRUS-HCM PART D DATA IN Q2 2026  BOULDER, COLO., JUNE 1, 2026 /PRNEWSWIRE/ --EDGEWISE THERAPEUTICS, INC. (NASDAQ: EWTX), A LEADING MUSCLE DISEASE BIOPHARMACEUTICAL COMPANY, TODAY ANNOUNCED THAT IT HAS ENTERED INTO A DEFINITIVE AGREEMENT UNDER WHICH SERVIER, AN INDEPENDENT INTERNATIONAL PHARMACEUTICAL GROUP GOVERNED BY A FOUNDATION, WILL ACQUIRE SEVASEMTEN AND EDGEWISE'S MUSCULAR DYSTROPHY BUSINESS FOR $1.55 BILLION IN UPFRONT CASH CONSIDERATION AND UP TO $1.1 BILLION IN ADDITIONAL MILESTONE PAYMENTS, FOR AGGREGATE POTENTIAL CONSIDERATION OF UP TO $2.65 BILLION.

EDGEWISE THERAPEUTICS ANNOUNCES SALE OF SEVASEMTEN FOR UP TO $2.65 BILLION, STRENGTHENING BALANCE SHEET AND CENTERING COMPANY FOCUS ON CARDIOVASCULAR PIPELINE

BOULDER, COLO., MAY 12, 2026 /PRNEWSWIRE/ -- EDGEWISE THERAPEUTICS, INC. (NASDAQ: EWTX), A LEADING MUSCLE DISEASE BIOPHARMACEUTICAL COMPANY, TODAY ANNOUNCED THAT EDGEWISE LEADERSHIP WILL PRESENT AT THE RBC CAPITAL MARKETS GLOBAL HEALTHCARE CONFERENCE ON WEDNESDAY, MAY 20, 2026, AT 10:00 AM ET.

EDGEWISE THERAPEUTICS TO PRESENT AT THE RBC CAPITAL MARKETS GLOBAL HEALTHCARE CONFERENCE ON MAY 20, 2026

 ANNOUNCED POSITIVE LONG-TERM SEVASEMTEN DATA DEMONSTRATING SUSTAINED FUNCTIONAL STABILIZATION IN BECKER MUSCULAR DYSTROPHY (BECKER) UP TO 3.5 YEARS OF FOLLOW-UP   CIRRUS-HCM 12-WEEK DATA OF EDG-7500 IN OBSTRUCTIVE AND NONOBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY (HCM) EXPECTED IN Q2 2026   PIVOTAL GRAND CANYON RESULTS FOR SEVASEMTEN IN BECKER EXPECTED IN Q4 2026  BOULDER, COLO., MAY 7, 2026 /PRNEWSWIRE/ -- EDGEWISE THERAPEUTICS, INC. (NASDAQ: EWTX), A LEADING MUSCLE DISEASE BIOPHARMACEUTICAL COMPANY, TODAY REPORTED FINANCIAL RESULTS FOR THE FIRST QUARTER OF 2026 AND RECENT BUSINESS HIGHLIGHTS.

Edgewise Therapeutics, Inc.

EWTX

Price

Financial Reports

No items found.

Press Releases

Edgewise Therapeutics, Inc.

EWTX.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

EWTX